U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Pediatric Advisory Committee
  5. Discussion and Voting Questions: Benefit-Risk Assessment of Prescription Opioid Antitussive Products for Treatment of Cough in Pediatric Patients
  1. Committees and Meeting Materials

Discussion and Voting Questions: Benefit-Risk Assessment of Prescription Opioid Antitussive Products for Treatment of Cough in Pediatric Patients

Discussion and Voting Questions: Benefit-Risk Assessment of Prescription Opioid Antitussive Products for Treatment of Cough in Pediatric Patients

Pediatric Advisory Committee Meeting

September 11, 2017

1. Discussion: Discuss the benefit/risk of the use of prescription codeine and hydrocodone antitussives in pediatric patients. 

a. What are the benefits and risks for the codeine and hydrocodone products intended for treatment of cough associated with allergy or the common cold?  In your deliberations, include the benefits and risks of these products for the patients as well as the wider public health impacts of opioid containing medications.

b. Does the benefit risk assessment change for treatment of cough in other specific circumstances?

c. Are there important differences in the benefit/risk between hydrocodone and codeine that would affect your recommendations about use in pediatric patients?

d. Are there differences in the benefit/risk assessment for specific pediatric age groups?

e. How do the wider public health concerns of opioid containing medications impact your benefit/risk assessment of codeine and hydrocodone products intended for treatment of cough?

2. Voting:  Is the benefit/risk favorable for use of prescription codeine cough suppressants for treatment of cough associated with allergy or the common cold in pediatric patients 12 to < 18="" years="" of="" age? ="" (yes="" or="" no) ="">
Provide the rationale for your vote. 

3. Voting:  Is the benefit/risk favorable for use of hydrocodone cough suppressants for treatment of cough associated with allergy or the common cold in pediatric patients:   

a. 6 to < 12="" years="" of="" age?="" (yes="" or="">

b. 12 to < 18="" years="" of="" age?="" (yes="" or="">

Provide the rationale for your vote. 

4. Voting:  Is the benefit/risk favorable for use of prescription opioid cough suppressants for treatment of cough in pediatric patients?  (Yes or No) 

Provide the rationale for your vote.